February 5, 2020

Axial Biotherapeutics to Present at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders’ Emerging Management Therapies for Childhood Neurodevelopmental Disorders Scientific Symposium

February 12, 2020

Axial Biotherapeutics Strengthens and Expands Board of Directors and Leadership Team

March 10, 2020

Axial Biotherapeutics to Present at the Chardan 2nd Annual Microbiome Medicines Virtual Summit

April 02, 2020

Axial Biotherapeutics Announces Positive Topline Results from Phase 1b/2a Clinical Trial of AB-2004 for the Treatment of Autism Spectrum Disorder

November 25, 2020

Axial Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

November 16, 2020

Axial Therapeutics to Participate in a Fireside Chat Hosted by LifeSci Capital

September 22, 2020

Axial Biotherapeutics Appoints Federico Bolognani, M.D., Ph.D., Vice President and Head of Clinical Science

September 15, 2020

Axial Biotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

August 12, 2020

Axial Biotherapeutics to Present at The JMP Securities CNS Forum

July 28, 2020

Axial Biotherapeutics Announces a Research Grant Award from The Michael J. Fox Foundation for the Development of an Enteric Nervous System Model to Assess Novel Parkinson’s Disease Therapeutics

May 27, 2020

Axial Biotherapeutics to Present at the Jefferies Virtual Global Healthcare Conference

May 22, 2020

Axial Biotherapeutics to Present Virtual Presentation at American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting

December 3, 2020

Results from Axial Therapeutics Phase1b/2a Study of AB-2004 in Adolescents with Autism Spectrum Disorder Met Primary Endpoint and Reduced Irritability and Other Symptoms

December 8, 2020

Axial Therapeutics to Present at the 2020 RBC Capital Markets Healthcare Private Company Conference

December 30, 2020

Axial Therapeutics to Present at the ACCESS CHINA Forum @JPM WEEK 2021